Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oligodendroglioma 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Gliosarcoma 1Glioma 1Glioblastoma 1Congenital Abnormalities 1Brain Neoplasms 1Blast Crisis 1Astrocytoma 1

Interventions

Temozolomide 27Radiotherapy 21Radiation 11Radiotherapy, Conformal 10Surgical Procedures, Operative 9Magnetic Resonance Spectroscopy 8Carmustine 8Radiotherapy, Intensity-Modulated 7Erlotinib Hydrochloride 7temsirolimus 6Vorinostat 6Sirolimus 6Chemotherapy, Adjuvant 6Bevacizumab 6motexafin gadolinium 5cediranib 5Cilengitide 5Carboplatin 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5tipifarnib 4Sorafenib 4Immunoglobulin G 4Disulfides 4Congresses as Topic 4Procarbazine 3O(6)-benzylguanine 3Nivolumab 3Neoadjuvant Therapy 3Lapatinib 3Ipilimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Gliosarcoma × octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate × Clear all
NCT01051557 2021-07-19

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
36 enrolled 15 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡